Меню
Vol. 1 No. 30 (2026) / 2026-03-30 / Number of views: 126
Authors
Keywords
Link to DOI:
How to quote
The article presents the results of scientific research on the synthesis and development of a technological scheme for the production of a substance of the new drug gincazon, which has antiviral activity. The ginkasone substance was obtained on the basis of a chemical modification of the well-known anti-tuberculosis drug isoniazid (IAH) in reaction with 2-formylbenzoic acid. The structure of the substrate and its clathrate complex was determined by modern physicochemical methods of IR- (KBr), 1H and 13C NMR spectroscopy (DMSO-d6 and CDCl3). The water-soluble gincazon inclusion complex was obtained by encapsulation of 2-((2-isonicotinoylhydrazone)methyl)benzoic acid using starch β-oligosaccharide (food component E-459) from an aqueous alcohol solution. Molecular modeling of the mechanism of formation of clathrate complexes of substrate inclusion has been carried out. The viral inhibitory activity of the compound sample for determining the chemical therapeutic index was studied at concentrations from 0.0016% to 0.2%, which corresponded to doses of 0.003-0.4 mg per chicken embryo (0.06-8 mg/kg). The virus-inhibiting activity of the new compound is twice as high as that of tamiflu and remantadine. The new compound and its water-soluble complex are characterized by a high chemical-therapeutic index, which creates prospects for further use in pharmacological research.